SENS-08

About Sensorium Therapeutics

Sensorium Therapeutics is a Boston-based, private biotech founded in 2021, operating in the psychedelics and broader CNS therapeutic sector. The company's core asset is the SensAI™ knowledge graph platform, which integrates over 50 million relationships across natural compounds, human experience, pharmacology, and neuroscience to derisk and accelerate drug discovery. This platform has generated a pipeline of three programs in under three years, led by SENS-01, a first-in-class serotonin modulator currently in Phase 1 trials for social anxiety disorder, with additional programs targeting drug-resistant epilepsy and Alzheimer's-related cognitive impairment.

Therapeutic Areas